Integra LifeSciences Holdings
The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Integra LifeSciences Holdings's revenues will wither -1.3% and EPS will compress -28.4%.
The average estimate for revenue is $207.5 million. On the bottom line, the average EPS estimate is $0.53.
Last quarter, Integra LifeSciences Holdings booked revenue of $196.7 million. GAAP reported sales were 0.2% higher than the prior-year quarter's $196.2 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, non-GAAP EPS came in at $0.39. GAAP EPS were -$0.15 for Q1 compared to $0.23 per share for the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 61.5%, 280 basis points worse than the prior-year quarter. Operating margin was 6.8%, 680 basis points worse than the prior-year quarter. Net margin was -2.1%, 550 basis points worse than the prior-year quarter.
The full year's average estimate for revenue is $843.6 million. The average EPS estimate is $2.49.
The stock has a four-star rating (out of five) at Motley Fool CAPS, with 152 members out of 164 rating the stock outperform, and 12 members rating it underperform. Among 57 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 54 give Integra LifeSciences Holdings a green thumbs-up, and three give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Integra LifeSciences Holdings is hold, with an average price target of $44.77.
Is Integra LifeSciences Holdings the best health care stock for you? Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks," including one above-average health care logistics company. Click here for instant access to this free report.
- Add Integra LifeSciences Holdings to My Watchlist.